Biosimilars in China: Firms await CFDA regulations this year
HONG KONG – A framework of the guidelines for biosimilar approvals in China should be released in June, and work proceeds apace to have regulations in place by the end of the year, industry insiders told BioWorld Asia.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter